AlzeCure Pharma 관리

관리 기준 확인 3/4

AlzeCure Pharma CEO는 Martin Jönsson, Jan2020 에 임명되었습니다 의 임기는 4.83 년입니다. 총 연간 보상은 SEK 2.48M, 76.6% 로 구성됩니다. 76.6% 급여 및 23.4% 보너스(회사 주식 및 옵션 포함). 는 SEK 669.48K 가치에 해당하는 회사 주식의 0.46% 직접 소유합니다. 669.48K. 경영진과 이사회의 평균 재임 기간은 각각 4.8 년과 3.5 년입니다.

주요 정보

Martin Jönsson

최고 경영자

SEK 2.5m

총 보상

CEO 급여 비율	76.6%
CEO 임기	4.8yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	4.8yrs
이사회 평균 재임 기간	3.5yrs

최근 관리 업데이트

Recent updates

Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares

Feb 03

We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate

Dec 13

CEO 보상 분석

Martin Jönsson 의 보수는 AlzeCure Pharma 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-SEK 36m
Jun 30 2024	n/a	n/a	-SEK 36m
Mar 31 2024	n/a	n/a	-SEK 37m
Dec 31 2023	SEK 2m	SEK 2m	-SEK 37m
Sep 30 2023	n/a	n/a	-SEK 38m
Jun 30 2023	n/a	n/a	-SEK 42m
Mar 31 2023	n/a	n/a	-SEK 53m
Dec 31 2022	SEK 2m	SEK 2m	-SEK 56m
Sep 30 2022	n/a	n/a	-SEK 68m
Jun 30 2022	n/a	n/a	-SEK 73m
Mar 31 2022	n/a	n/a	-SEK 67m
Dec 31 2021	SEK 2m	SEK 2m	-SEK 78m
Sep 30 2021	n/a	n/a	-SEK 73m
Jun 30 2021	n/a	n/a	-SEK 78m
Mar 31 2021	n/a	n/a	-SEK 81m
Dec 31 2020	SEK 2m	SEK 1m	-SEK 71m

보상 대 시장: Martin 의 총 보상 ($USD 227.04K )은 Swedish 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 237.78K ).

보상과 수익: 회사가 수익성이 없는 동안 Martin 의 보상이 증가했습니다.

CEO

Martin Jönsson (56 yo)

4.8yrs

테뉴어

SEK 2,475,000

보상

Mr. Martin Jönsson is the Chief Executive Officer of AlzeCure Pharma AB (publ) since January 8, 2020. Mr. Jönsson served in a senior position at Ferring Pharmaceuticals in the US, he was business area dire...

리더십 팀

이름	위치	테뉴어	보상	소유권
Martin Jönsson	Chief Executive Officer	4.8yrs	SEK 2.48m	0.46% SEK 669.5k
Birgitta Lundvik	Chief Financial Officer	7.8yrs	데이터 없음	0.14% SEK 200.3k
Johan Sandin	Chief Scientific Officer	4.8yrs	SEK 1.28m	0.99% SEK 1.4m
Marta Storck	Chief Medical Officer & Head of Development	3.6yrs	데이터 없음	0.084% SEK 121.3k
Pontus Forsell	Head of Research & Discovery	7.8yrs	데이터 없음	1.03% SEK 1.5m

4.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: ALZCUR 의 관리팀은 경험 ( 4.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas Pollare	Chairman	7.8yrs	SEK 229.00k	1.7% SEK 2.5m
Jan Lundberg	Director	less than a year	데이터 없음	데이터 없음
Ragnar Linder	Independent Director	7.8yrs	SEK 115.00k	0.056% SEK 81.3k
John Harrison	Scientific Advisor	no data	데이터 없음	데이터 없음
Bengt Winblad	Scientific Advisor	no data	데이터 없음	데이터 없음
Peter Snyder	Scientific Advisor	no data	데이터 없음	데이터 없음
Henrik Zetterberg	Scientific Advisor	no data	데이터 없음	데이터 없음
Rolf Karlsten	Scientific Advisor	no data	데이터 없음	데이터 없음
Janet Hoogstraate	Independent Director	1.5yrs	SEK 73.00k	0.028% SEK 40.9k
Sven Ogren	Scientific Advisor	no data	데이터 없음	데이터 없음
Eva Lilienberg	Independent Director	3.5yrs	SEK 115.00k	0.0028% SEK 4.1k

3.5yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: ALZCUR 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.

AlzeCure Pharma 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Appoints Janet Hoogstraate to its Board

AlzeCure Pharma AB (publ), Annual General Meeting, May 17, 2023

Chief Executive Officer recently bought kr163k worth of stock

Chief Executive Officer recently bought kr163k worth of stock

Recent updates

AlzeCure Pharma AB (publ) Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis

AlzeCure Pharma AB (publ) to Report Q2, 2025 Results on Aug 26, 2025

AlzeCure Pharma AB (publ) Announces an Abstract with Preclinical Data on NeuroRestore ACD856 Demonstrating Its Anti-In-In-In-Class Drug Candidate for Alzheimer's Disease

AlzeCure Pharma AB (publ) Announces New Results from Alzecure's Pain Project TrkA- NAM Presented At the Pain Conference IASP 2024

New minor risk - Shareholder dilution

Alzecure Pharma AB (Publ) Announces Positive Clinical Results with Painless ACD440 Against Neuropathic Pain

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

AlzeCure Pharma AB (publ) Approves the Election of Jan Lundberg as New Ordinary Members of the Board of Directors

Price target decreased by 10% to kr13.00

AlzeCure Pharma AB (publ) Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024

New major risk - Market cap size

AlzeCure Pharma AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 52.77396 million.

AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at Leading Alzheimer's Conference

AlzeCure Pharma AB (publ) Publishes Clinical Results Supporting Continued Development of NeuroRestore ACD856 Against Alzheimer's

New minor risk - Share price stability

AlzeCure Pharma AB (publ) Gets Late Breaking Abstract of New Preclinical Data with ACD856 Accepted at AD/PD 2024 Conference

AlzeCure Pharma AB (publ) Selects Drug Candidate and Enters Next Phase of Development with Trka-Nam Acd137 Against Severe Pain

We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth

AlzeCure Pharma AB (publ) Presents Disease-Modifying Data with NeuroRestore ACD856 At Alzheimer's Conference CTAD

AlzeCure Pharma AB (publ) Announces Japenese Patent Office Grants Patent Covering its Leading Candidate Drug ACD856

Alzecure Presents Clinical Phase Ii-Data with Acd440 for Neuropathic Pain At Pain Conference

AlzeCure Gets Presentation Accepted on Disease-Modifying Effects of Acd856 At Alzheimer's Conference

AlzeCure Pharma AB (publ) Presents Positive Phase II Clinical Data with ACD440 Against Neuropathic Pain at EFIC 2023 Conference

AlzeCure Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 04, 2024

New minor risk - Financial position

AlzeCure Pharma AB (publ) to Report Q4, 2023 Results on Feb 27, 2024

AlzeCure Pharma Publishes the Positive Clinical Results from the Phase I Trial of NeuroRestore ACD856 Against Alzheimer's

Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth

AlzeCure Pharma AB (Publ) Publishes New Disease Modifying Data with Neurorestore ACD856 Against Alzheimer's and Cognitive Disorders

Alzecure Announces Positive Phase IIa Clinical Study Data in Neuropathic Pain with the Non-Opioid ACD440

AlzeCure Pharma AB (publ) Appoints Janet Hoogstraate to its Board

Forecast to breakeven in 2025

Last Patient Included in Alzecure's Phase II Clinical Trial in Peripheral Neuropathic Pain with The Non-Opioid ACD440

AlzeCure Pharma AB (publ) Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer's

Alzecure Pharma AB (Publ) Gets Abstract Accepted on New Potential Disease-Modifying Effects of ACD856 Against Alzheimer's

AlzeCure Pharma AB (publ) Gets Late-Breaking Abstract on New Data with Alzheimer Project

Alzecure Pharma AB (Publ) Announces New Data on Alzstatin for Preventive Treatment Against Alzheimer's Presented At Alzheimer's Conference CTAD

Alzheimer Announces New Data Strengthening the Continued Clinical Development of NeuroRestore ACD856

Price target decreased to kr12.00

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Positive Clinical EEG Results with Alzheimer's Project NeuroRestore ACD856

Price target decreased to kr12.00

Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely?

AlzeCure Pharma AB (publ) Announces New Data from AlzeCure Demonstrate Potential Disease-Modifying Effects of NeuroRestore ACD856

AlzeCure Presents New Data on the Anti-Inflammatory Effects of its TrkA-NAM Pain Project at IASP 2022

AlzeCure's Alzheimer’s Project NeuroRestore ACD856 Shows Positive Effect on Brain Activity in Clinical Trial

AlzeCure Pharma AB (publ), Annual General Meeting, May 17, 2023

AlzeCure Pharma AB (publ) Gets Abstract Accepted on Potential Neuroprotective Effects of NeuroRestore ACD856

AlzeCure Pharma AB Gets Abstract on New Clinical Study Data with NeuroRestore Accepted At the Alzheimer's Conference Aaic

AlzeCure Pharma AB (Publ) Announces Update on Clinical Phase I Study

AlzeCure Pharma AB (publ) Announces First Patient Included in its Phase II Clinical Trial in Neuropathic Pain with Non-Opioid ACD440

Alzecure Pharma AB (Publ)'s Abstract on Pain Project TrkA-NAM Accepted for Presentation At IASP 2022

AlzeCure Pharma AB (publ) Gets Approval to Start Phase II Clinical Trial with Non-Opioid Pain Project ACD440

AlzeCure Pharma AB (publ) Publishes New Data on Alzstatin from Alzheimer Conference

AlzeCure Publishes New Data on NeuroRestore and Acd856 from Alzheimer's Conference

Chief Executive Officer recently bought kr163k worth of stock

Chief Executive Officer recently bought kr163k worth of stock

Chief Financial Officer recently bought kr120k worth of stock

Alzecure Pharma AB (Publ) Receives Positive Indicative Clinical Data with Acd856 in Development for Alzheimer's Disease

Alzecure Pharma AB (publ) Announces Moving Towards Phase IIa Clinical Trial with ACD440 Based on Guiding Response from the FDA

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Price target increased to kr21.90

AlzeCure Pharma AB (publ) to Present Abstract at ECNP Conference on NeuroRestore Project's Potential in Depression

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?

AlzeCure Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

AlzeCure Pharma AB (publ) to Report Q2, 2021 Results on Aug 25, 2021

New 90-day low: kr7.50

Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares

New 90-day low: kr8.16